Evaluation of PD-1 and interleukin-10-receptor expression by T lymphocytes in malignant and benign pleural effusions

Author:

Mosleh Berta1,Hammer Barbara2,El-Gazzar Ahmed3,Kramer Markus3,Ayazseven Seda3,Bernitzky Dominik1,Geleff Silvana3,Idzko Marco1,Gompelmann Daniela1,Hoda Mir Alireza1

Affiliation:

1. Medical University of Vienna, Comprehensive Cancer Center Vienna

2. Member of the German Center for Lung Research (DZL)

3. Medical University of Vienna

Abstract

Abstract

Background: PD-1 (programmed cell death protein-1)/PD-L1 (programmed cell death ligand-1) as well as IL-10 (interleukin-10)/IL-10R (interleukin-10 receptor) interactions play a major role in tumor immune evasion in various malignancies. Several studies investigated the expression of PD-1 on T lymphocytes in pleural effusions (PE) in patients with malignant diseases. However, results in malignant pleural effusions (MPE) compared to benign PE (BPE) are underreported. Methods: In this prospective study, 51 patients (median age 66 years, IQR 54–78, 47% male) with PE of malignant or benign origin were enrolled and divided into three groups according to the cytological results (group 1: MPE [n = 24, 47%]; group 2: BPE in malignant disease [n = 22, 43%]; group 3: BPE in benign disease [n = 5, 10%]). In the cytological samples, T cells were analyzed for the expression of PD-1 and IL-10R via flow cytometry. Results: In MPE, the proportion of PD-1 + T lymphocytes on CD4 + cells was significantly lower than in BPE (group 1 vs 3, p = 0.019). Moreover, a significantly lower expression of PD-1 + IL-10R + CD8+ (group 1 vs 2, p = 0.016; group 1 vs 3, p = 0.032) and a significantly higher expression of PD-1-IL-10R-CD8 + T lymphocytes (group1 vs 2, p = 0.045; group 1 vs 3, p = 0.032) were observed in MPE when compared to BPE. Conclusion: The frequency of T cells expressing PD-1 and IL-10R is significantly lower in MPE compared to BPE regardless of the underlying disease indicating a different microenvironment in PE driven by the presence of tumor cells. Our observation spotlights the possible involvement of PD-1 and IL-10R in MPE.

Publisher

Research Square Platform LLC

Reference34 articles.

1. PD-L1 testing by immunohistochemistry in immuno-oncology;Vranic S;Biomol Biomed,2023

2. PD-1 and PD-L1 in cancer immunotherapy: clinical implications and future considerations;Jiang Y;Hum Vaccin Immunother,2019

3. PD-1/PD-L1 pathway: current researches in cancer;Han Y;Am J Cancer Res,2020

4. Beyond immune checkpoint blockade: emerging immunological strategies;Kubli SP;Nat Rev Drug Discov,2021

5. Immune Checkpoint Inhibitors in Thoracic Malignancies: Review of the Existing Evidence by an IASLC Expert Panel and Recommendations;Remon J;J Thorac Oncol,2020

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3